Thomas A. Raffin - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Reporting relationship: Director
Issuer ticker: AKYA
Reported as of: 08 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2025, 20:37:37 UTC
Prior SEC filing: 13 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Thomas A. Raffin

Key filing fact

Thomas A. Raffin filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 10 Jul 2025.

Key facts

This page summarizes Thomas A. Raffin's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
7 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 10 Jul 2025, 20:37.

Change

Previous filing in this sequence was filed on 13 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001512119 Primary reporting owner

Raffin Thomas A.

Relationship: Director
Address: C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH
Signature: /s/ Thomas A. Raffin
Signature date: 10 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKYA transaction

Common Stock

Other

Transaction value
Shares: -234,592
Change %: -100%
Price
Shares after: 0
Date: 08 Jul 2025
Ownership: Thomas A. Raffin Living Trust dated March 29, 2017
Footnotes: F1, F2

AKYA transaction

Common Stock

Other

Transaction value
Shares: -1,737,712
Change %: -100%
Price
Shares after: 0
Date: 08 Jul 2025
Ownership: See footnote 3
Footnotes: F1, F2, F3

AKYA transaction

Common Stock

Other

Transaction value
Shares: -15,937,535
Change %: -100%
Price
Shares after: 0
Date: 08 Jul 2025
Ownership: See footnote 4
Footnotes: F1, F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKYA transaction Derivative

Stock Option (Right to Buy)

Other

Transaction value: $0
Shares: -16,860
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,860
Exercise price: $21.95
Footnotes: F5, F6

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -30,549
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,549
Exercise price: $11.24
Footnotes: F5, F6

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -56,322
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,322
Exercise price: $5.70
Footnotes: F5, F6

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -50,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $2.01
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Thomas A. Raffin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.

Footnote F2

In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.

Footnote F3

Shares held directly by THP III Affiliates Fund, LLC ("THP III AFF"). Telegraph Hill Partners III Investment Management, LLC ("THP IM") is the manager of THP III AFF. Telegraph Hill Partners Management Company, LLC ("THPMC") is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III AFF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Footnote F4

Shares held directly by Telegraph Hill Partners III, L.P. ("THP III"). THP IM is the general partner of THP III. THPMC is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Footnote F5

Disposition of options pursuant to Merger Agreement.

Footnote F6

Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.